Shanghai Haohai Biological Technology 

$0.000000
0
+$0.00+0%星期一 00:00

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
-
股息
-

即將到來

股息

0%股息殖利率
2026年10月
$0.04
2026年7月
$0.09
2025年10月
$0.06
2025年7月
$0.08
2024年10月
$0.06
10年成長
11.22%
5年成長
17.69%
3年成長
45.85%
1年成長
-10.63%

財報

10月23日預期
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q3 2026
0.03
0.04
0.04
0.05
預期EPS
不適用
實際EPS
0.029245354313999997

財務

10.18%利潤率
有盈利
2020
2021
2022
2023
2024
2025
345.35M營收
35.17M淨利

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and commercialization of biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various other international regions. A comprehensive product portfolio addresses several key medical disciplines. Within ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. Orthopedics products encompass sodium hyaluronate injections and medical chitosan. For wound repair, it manufactures recombinant human epidermal growth factor, effective in treating burn wounds, residual wounds, donor site post-traumatic wounds, and both fresh and chronic ulcerations. Additionally, the company develops anti-adhesion materials, including medical sodium hyaluronate gel and medical chitosan, as well as hemostatic solutions such as collagen sponges and porcine fibrin sealants. Beyond its therapeutic offerings, Shanghai Haohai maintains a significant presence in the medical aesthetics market. This segment features a range of hyaluronic acid (HA) dermal fillers: Matrifill, positioned as a first-generation mono-phase injectable HA gel; Janlane, a second-generation filler engineered for dynamic application; and Hyalumatrix, a third-generation product providing precise aesthetic embellishment. Its aesthetic portfolio is further complemented by radio frequency devices and laser equipment. Furthermore, the company actively engages in the research and development of biological engineering and pharmaceutical products, extending services such as technology transfer and consultation. It also conducts investment and trading operations. Established in 2007, the entity initially traded as Haohai Limited before officially adopting the name Shanghai Haohai Biological Technology Co., Ltd. in 2010. Its corporate headquarters are based in Shanghai, China.
顯示更多
執行長
Wu Jianying
員工
2110
國家
中國
ISIN
CNE100001W69
WKN
000A14SA6

上市

0 則留言

分享你的想法

常見問題

Shanghai Haohai Biological Technology 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 OTC Link 交易所,Shanghai Haohai Biological Technology 的股票以代號 SHBTF 進行交易。
Shanghai Haohai Biological Technology 下一次財報日期是什麼時候?▼
Shanghai Haohai Biological Technology 將於 2027年3月22日 公布下一次財報。
Shanghai Haohai Biological Technology 上一季度的財報如何?▼
SHBTF 上一季度的財報為每股 0.03 USD,預估為 不適用 USD,帶來 不適用 的驚喜。下一季度的預估財報為每股 不適用 USD。
Shanghai Haohai Biological Technology 去年的營收是多少?▼
Shanghai Haohai Biological Technology 去年的營收為 345.35MUSD。
Shanghai Haohai Biological Technology 去年的淨利是多少?▼
SHBTF 去年的淨收益為 35.17MUSD。
Shanghai Haohai Biological Technology 會發放股息嗎?▼
是的,SHBTF 的股息每 半年一次 發放一次。每股最新股息為 0.04 。截至今日,股息殖利率(FWD)% 為 0%。
Shanghai Haohai Biological Technology 有多少名員工?▼
截至 2026年11月22日,公司共有 2,110 名員工。
Shanghai Haohai Biological Technology 位於哪個產業?▼
Shanghai Haohai Biological Technology從事於Health & Wellness產業。
Shanghai Haohai Biological Technology 何時完成拆股?▼
Shanghai Haohai Biological Technology 上次拆股發生於 2024年6月6日,比例為 14:10。
Shanghai Haohai Biological Technology 的總部在哪裡?▼
Shanghai Haohai Biological Technology 的總部位於 中國 的 Shanghai。